Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;165(3):355-368.
doi: 10.1111/imm.13442. Epub 2022 Jan 10.

Eosinophil plays a crucial role in intestinal mucositis induced by antineoplastic chemotherapy

Raquel D N Arifa  1 , Camila B Brito  1 , Talles P de Paula  1 , Renata L Lima  1 , Zélia Menezes-Garcia  1 , Puebla Cassini-Vieira  2 , Fabrício A Vilas Boas  2 , Celso M Queiroz-Junior  3 , Janine M da Silva  3 , Tarcília A da Silva  3 , Lucíola S Barcelos  2 , Caio T Fagundes  1   4 , Mauro M Teixeira  4   5 , Daniele G Souza  1
Affiliations
Free article

Eosinophil plays a crucial role in intestinal mucositis induced by antineoplastic chemotherapy

Raquel D N Arifa et al. Immunology. 2022 Mar.
Free article

Abstract

Mucositis is a major clinical complication associated with cancer treatment and may limit the benefit of chemotherapy. Leukocytes and inflammatory mediators have been extensively associated with mucositis severity. However, the role of eosinophils in the pathophysiology of chemotherapy-induced mucositis remains to be elucidated. Here, using GATA-1-deficient mice, we investigated the role of eosinophils in intestinal mucositis. There was marked accumulation of eosinophils in mice given irinotecan and eosinophil ablation inhibited intestinal mucositis. Treatment with Evasin-4, a chemokine receptor antagonist, reduced the recruitment of eosinophils and decreased irinotecan-induced mucositis. Importantly, Evasin-4 did not interfere negatively with the antitumour effects of irinotecan. Evasin-4 was of benefit for mice given high doses of irinotecan once Evasin-4-treated mice presented delayed mortality. Altogether, our findings suggest that Evasin-4 may have significant mucosal-protective effects in the context of antineoplastic chemotherapy and may, therefore, be useful in combination with anticancer treatment in cancer patients.

Keywords: Evasin-4; eosinophils; intestinal inflammation; irinotecan; mucositis.

PubMed Disclaimer

References

REFERENCES

    1. Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2008;52:61-77, viii.
    1. Sonis ST. A biological approach to mucositis. J Support Oncol. 2004;2:21-32. discussion 5-6.
    1. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277-84.
    1. Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66:253-62.
    1. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98:1531-9.

Publication types

LinkOut - more resources